All In Biotech

Drug Trial Radar · NCT00435461

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis

Last checked: Nov 19, 2026Latest source record: Mar 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Actual

Start

Dec 20, 2006

Primary completion

Feb 1, 2007

Study completion Feb 28, 2007

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 15, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the nighttime symptom relief of fluticasone furoate nasal spray and oral fexofenadine

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

  • Fluticasone furoate and fexofenadineDrug

    Fluticasone furoate and fexofenadine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Symptoms Score (NSS)Time frame: Baseline (Day 1) and up to 2 Weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Kerrville, Texas

  • GSK Investigational Site

    New Braunfels, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.